3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Burkitt Lymphoma
1
Interventions
venetoclax
26
ibrutinib
23
Rituximab
22
Cyclophosphamide
21
obinutuzumab
18
acalabrutinib
18
fludarabine phosphate
13
fludarabine
13
zanubrutinib
8
Bendamustine Hydrochloride
8
pirtobrutinib
7
Biopsy
7
Specimen Handling
6
Lenalidomide
6
CT-P10
6
Whole-Body Irradiation
5
Tacrolimus
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
duvelisib
3
Melphalan
3
Chlorambucil
3
Busulfan
3
idelalisib
2
daratumumab
2
Vincristine
2
Prednisone
2
Patient Reported Outcome Measures
2
Observation
2
Mesna
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
Maintenance
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled